GlassScriptPhysician profile
Wendy Mak
NPI 1508250036
$940.86
in general payments reported to CMS, 2019-2025
12 companies · $57.98 in 2025
The $57.98 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $213 · 2023: $383 · 2024: $286 · 2025: $57.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $713 · Travel and Lodging: $15.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $712.62 |
| Travel and Lodging | $15.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $310.69 | 2022-2024 | Mounjaro |
| Glaxosmithkline, LLC. | $167.65 | 2022-2023 | Rotarix, Bexsero, Pediarix |
| Amgen INC. | $125.00 | 2023 | Repatha |
| Novo Nordisk INC | $91.45 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Abiomed | $53.84 | 2023 | Impella |
| Viiv Healthcare Company | $45.54 | 2024 | Apretude |
| Sanofi Pasteur INC. | $35.84 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.85 | 2024 | |
| Exeltis, USA INC. | $22.08 | 2025 | Slynd |
| Hologic Sales and Service, LLC | $20.47 | 2023 | Thinprep 2000 Processor, Aptima |
| Merck Sharp & Dohme LLC | $20.00 | 2022 | |
| Agios Pharmaceuticals, INC. | $17.45 | 2025 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Mak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.